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Abstract
Background: Cardiovascular events are frequent and vascular endothelial function is abnormal in patients with chronic
kidney disease (CKD). We demonstrated endothelial dysfunction with vitamin D deficiency in CKD patients; however the
impact of cholecalciferol supplementation on vascular stiffness and vasomotor function, endothelial and bone biomarkers
in CKD patients with low 25-hydroxy vitamin D [25(OH)D] is unknown, which this study investigated.
Methods: We assessed non-diabetic patients with CKD stage 3/4, age 17–80 years and serum 25(OH)D,75 nmol/L. Brachial
artery Flow Mediated Dilation (FMD), Pulse Wave Velocity (PWV), Augmentation Index (AI) and circulating blood biomarkers
were evaluated at baseline and at 16 weeks. Oral 300,000 units cholecalciferol was administered at baseline and 8-weeks.
Results: Clinical characteristics of 26 patients were: age 50614 (mean61SD) years, eGFR 41611 ml/min/1.73 m2, males
73%, dyslipidaemia 36%, smokers 23% and hypertensives 87%. At 16-week serum 25(OH)D and calcium increased (43616
to 84629 nmol/L, p,0.001 and 2.3760.09 to 2.4260.09 mmol/L; p = 0.004, respectively) and parathyroid hormone
decreased (10.868.6 to 7.464.4; p = 0.001). FMD improved from 3.163.3% to 6.163.7%, p = 0.001. Endothelial biomarker
concentrations decreased: E-Selectin from 566662123 to 525662058 pg/mL; p = 0.032, ICAM-1, 3.4560.01 to
3.1061.04 ng/mL; p = 0.038 and VCAM-1, 54633 to 42633 ng/mL; p = 0.006. eGFR, BP, PWV, AI, hsCRP, von Willebrand
factor and Fibroblast Growth Factor-23, remained unchanged.
Conclusion: This study demonstrates for the first time improvement of endothelial vasomotor and secretory functions with
vitamin D in CKD patients without significant adverse effects on arterial stiffness, serum calcium or FGF-23.
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Introduction
Patients with chronic kidney disease (CKD) have up to 3.5 fold
increased risk of cardiovascular (CV) events and cardiovascular
disease (CVD) is the most common cause of mortality and
morbidity [1]. Evidence from general population surveys has
shown that CKD is an independent risk factor for CVD [2].
Vascular atherosclerosis is a predominant cause of CV events in
CKD, with endothelial cell activation as its primary inciting event
[3,4]. Endothelial dysfunction is the final common pathway of
vascular injury mediated by both traditional and non-traditional
risk factors of CVD [5]. Circulating biomarkers of endothelial cell
activation such as Intracellular Adhesion Molecule (ICAM),
Vascular Adhesion Molecule (VCAM), Endothelial leucocyte
adhesion molecule (E-Selectin) and platelet adhesion molecule,
such as von willebrand factor (vWF), have been validated for
assessment of endothelial function [6]. Flow mediated dilatation
(FMD) of the brachial artery in response to distal ischaemia, has
been validated for assessment of endothelial function in-vivo [6].
Brachial artery FMD is a surrogate for CV disease, as it correlates
with coronary atherosclerosis [7]. FMD has been shown to predict
future CV events and mortality in the general population and in
patients with mild to moderate CKD [8,9]. Additionally, it has
been used extensively to study the effects of pharmacological
therapies on vascular function in-vivo [10–12]. More importantly,
an improvement in endothelial function, as measured by brachial
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artery FMD, may relate to better prognosis in patients with
atherosclerotic disease [13].
Low vitamin D is associated with endothelial dysfunction and
high CV mortality in patients with CKD [14,15]. Native vitamin
D treatment has been shown to improve endothelium mediated
vascular responses in experimental studies. Studies on spontane-
ously hypertensive rats show an improvement in vascular response
to acetylcholine following a 6 week treatment with vitamin D
[16,17]. In type II diabetic patients and 25-hydroxy vitamin D
[25(OH)D] deficiency, vitamin D2 treatment over 8 weeks
significantly improved brachial artery FMD [18]. We have
previously reported an association between reduced vitamin D
levels and impaired brachial artery FMD in CKD patients [14].
However, it is unknown if vitamin D supplementation is associated
with an improvement in endothelial function in patients with
CKD.
Serum Fibroblast Growth Factor-23 (FGF-23) a phosphaturic
hormone secreted by osteoblasts, inhibits 1 alpha hydroxylase
enzyme, preventing conversion of 25 (OH)D to 1,25 dihydroxy
vitamin D [1,25 (OH)2D] is elevated in CKD, and associated with
mortality, coronary artery atherosclerosis and left ventricular
hypertrophy [19–21]. However, it is not known if nutritional
vitamin D treatment in vitamin D insufficient/deficient CKD
patients, changes serum FGF-23 levels.
As the impact of Vitamin D supplementation on arterial
vasomotor and stiffness function, endothelial and bone biomarkers
has not been investigated systematically, this study tested the effect
of treatment with oral cholecalciferol on endothelial function,
arterial stiffness, biomarkers of endothelial cell activation and
serum FGF-23, in relatively healthy non-diabetic CKD stage 3
and 4 patients with low levels of vitamin D.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The brief methods are as follows.
1. Patients
Stable (past 6 months) stage 3–4 CKD patients, with low
vitamin D (25(OH)D,75 nmol/L), were recruited. Baseline
serum 25 (OH)D were measured during routine clinic visits for
patients. Patients were excluded from the study if they were known
to have diabetes mellitus, malignancy, heart failure (Ejection
fraction on ECHO,40% or N-terminal pro Brain natriuretic
peptide (NT-proBNP).500 pg/ml), active inflammation, active
autoimmune conditions, recent acute coronary syndrome (within
last 3 months), rapidly deteriorating renal function, corrected
serum calcium.2.55 mmol/L and if already on Vitamin D
supplementation. Patients were considered to have diabetes
mellitus if they were on insulin, oral hypoglycaemic agents,
diagnosed as diet controlled diabetes, had a fasting blood sugar
$7 mmol/L or random glucose $11.1 mmol/L. The study was
approved by NRES Surrey Research Ethics committee (REC
reference 10/H1109/14) and all patients provided written
informed consent. Patient recruitment and follow up is represented
in figure 1. Patients were recruited between June 2010 and May
2012 follow up completed in September 2012. The trial was
registered after study completion to ensure proper conduct and we
confirm that all on-going and related trials with Vitamin D are
registered.
2. Brachial artery FMD
Brachial artery FMD was estimated at baseline and on follow up
at 16 weeks. All study subjects were assessed in our vascular
laboratory, in a quiet purpose-built room maintained at constant
temperature of 22–24uC, after 10 min of rest in the supine
position, and after 12 hour overnight fasting. Patients were asked
to withhold their regular medications for the day, until after the
scan. Caffeine and tobacco were disallowed in the 6 hours prior to
the scan. A standard HDI (High Definition Imaging) 3000
ultrasound system (ATL, Bothell, WA, USA) equipped with a
12–5 MHz linear array transducer was used for endothelial
function measurements. The same trained physician performed all
scans. The overall mean (SD) intra patient variability of this
technique within our department is 0.9 (0.48) % (range 0.21–2%)
[22].
The right arm brachial artery was scanned in a longitudinal
section 2–10 cm above the elbow and its diameter measured
continuously with on-line, wall-tracking software for 1 min at
baseline, during 4.5 min of induced distal ischaemia (induced by
inflation to 300 mmHg of a pneumatic cuff placed at a site distal to
the segment of the artery being analysed), and for another 5 min
during reactive hyperaemia after cuff release. After return to
baseline, vessel diameter was again measured continuously up to
3 min for baseline measurements and for 5 min after administra-
tion of 50 mg sublingual glyceryl trinitrate, a direct nitric oxide
donor. FMD was defined as the maximum percentage increase in
vessel diameter during reactive hyperaemia; endothelium inde-
pendent FMD was defined as the maximum percentage increase in
vessel diameter after sublingual glyceryl trinitrate.
3. Pulse wave velocity and Augmentation index
The pulse wave velocity (PWV) was measured at baseline and at
week 16. This was done at the same time as the brachial artery
FMD. Arterial stiffness was assessed non-invasively using a
pressure tonometer coupled to a SphygmoCor PWV system. A
simultaneously recorded ECG signal (continuous recording of 3
chest leads) provided an R-wave timing reference. Pulsation from
two contra lateral recording sites, the common carotid artery and
the femoral artery were identified and marked. The distance
between the suprasternal notch and common carotid pulsation was
subtracted from the distance between the suprasternal notch and
the femoral artery pulse to obtain the PWV distance. A pressure
tonometer was then placed at the two recording sites to obtain 10
homogenous continuous waveforms. The software processed each
set of pulse waveforms and ECG waveform data to calculate the
mean time difference between the arrivals of the pulse at the two
peripheral recording sites on a beat to beat basis. The PWV was
then calculated using the mean time difference and the arterial
path length between the two recording sites. At the same time
blood pressure was recorded over the right arm and a mean of
three readings was considered. Height (without footwear) and
weight (in street clothes) was measured and recorded in the
SphygmoCor PWV system. Using the same equipment, the radial
pulse waveform was analysed and the corresponding central aortic
waveform generated using a transfer function. The augmentation
index (AI) was calculated as the ratio of the difference between
early and peak systolic pressure versus the early systolic pressure
from the derived aortic wave form.
4. Measurement of circulating biomarkers
Whole blood samples were obtained in SST tubes during
baseline and follow-up scans. The samples were centrifuged
immediately at 4000 rpm for 15 minutes and the serum separated.
Serum was analysed for baseline 25(OH)D levels using a
Vitamin D and Endothelial Function in CKD
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chemiluminescent immunoassay on an automated IDS-iSYS
analyser. The analytical range was 12.5–350 nmol/L and inter-
batch co-efficient of variation (CV) ,12%. High sensitivity C-
reactive protein (hsCRP) was measured using the hsCRP latex-
enhanced immunoturbidimetric assay (Siemens Healthcare Diag-
nostics) on an ADVIA 2400 analyser. The analytical range was
0.16–10 mg/L and the inter batch CV,10%. The remaining
serum was stored at 270uC.
Baseline and follow-up serum samples for each patient were
measured simultaneously in duplicates for endothelial function
biomarkers, with mean value of the two concentrations taken as
the representative concentration of the biomarker in the sample.
Serum E-Selectin was measured using ELISA (Abcam). The
samples and the standards were diluted 1:100. The assay range for
this ELISA is 1600–50,000 pg/ml and the intra-assay and inter-
assay CV% is 5.4 and 6.0%, respectively.
Serum ICAM was measured using ELISA (Thermo Scientific).
The samples were diluted in the ratio of 1:100. The assay range for
this ELISA is 0.3–10 ng/ml and the intra-assay CV% is ,10%.
Serum vWF was measured using ELISA (Abcam). The samples
were diluted in the ratio of 1:100. The assay range for this ELISA
is 3–30 mU/ml and the intra-assay and inter-assay CV% is 5.1
and 7.2%, respectively (note 1 IU/ml = 9.8 mg/ml).
Soluble VCAM-1 (sVCAM-1) was measured using ELISA
(Invitrogen). The samples were diluted in the ratio of 1:50. The
assay range for this ELISA is 0–75 ng/ml and the intra-assay and
inter-assay CV% is ,4.6 and ,8.2%.
Serum FGF-23 was measured by second-generation ELISA
(Immutopics, Inc, San Clemente, California) detecting both intact
FGF-23 and C-terminal fragments. The interassay CV for this
assay was 8.6% and 7.8% at plasma concentrations of 34.6 and
280.8 RU/mL, respectively.
Figure 1. Number of patients recruited into the study and completed the follow-up. Legend: Flow Diagram of the patient pathway
recruited into the effects of oral vitamin D on endothelial function intervention study. Thirty five patients were recruited into the study after
excluding twenty one patients. Twenty six patients completed the study.
doi:10.1371/journal.pone.0091363.g001
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5. Vitamin D therapy
All patients recruited received 2 doses of oral 300,000 units of
Cholecalciferol in vegetable oil (Martindale Pharma) at the
beginning of the study and at week 8. This dose of cholecalciferol
has been found to be safe and effective in lowering serum
parathyroid hormone (PTH) levels in CKD 3/4 patients, without
hypercalcemia [23]. A study from our hospital in patients with 25
(OH)D,40 nmol/L, using 300,000 IU of the same preparation
showed a significant decline of 25 (OH)D levels at 12 weeks post
administration [24], hence we chose to readminister 300,000 units
at 8 weeks to maintain a biological effect of vitamin D3.
6. Statistical analysis
Data were analysed using Statistical Package for Social Sciences
(SPSSv.16, Chicago, IL). Continuous and normally distributed
variables are expressed as mean61SD. Continuous and non-
normally distributed variables are expressed as median6Inter-
quartile range (IQR). Categorical variables are expressed as
percentages (%). Comparison of means for continuous, parametric
variables was performed using dependent sample T-test and for
non-parametric variables using Wilcoxon signed rank test.
Comparison of categorical variables was performed using Chi-
squared testing. A twosided p-value of ,0.05 was considered to
indicate statistical significance.
7. Sample Size Calculation
The sample size was calculated to show a 10% improvement in
mean FMD with vitamin D treatment. The mean FMD of patients
recruited into our previous study was 3.8%. The standard
deviation of the intra-patient variability in FMD measurements,
is 0.48% (range: 0.21–2%) [22]. Taking a=0.05 and a b=20,
twenty-seven patients were required to show a 10% change in
FMD measurements. Assuming a dropout rate of 30% due to
failure of study follow-up, progression to ESRD, transfer to other
renal units or death, 35 patients were recruited into the study.
Results
Thirty five patients were recruited. Twenty six patients
completed the 16 week follow-up (figure 1). The baseline clinical
characteristics of these 26 patients are represented in table 1.
Thirteen patients were Caucasians with 6 South-East Asians, 6
Afro-Caribbeans and 1 of Chinese origin. Six patients had a family
history of ischaemic heart disease. Three patients had a history of
ischaemic heart disease, but none had suffered a myocardial
infarction (MI) or stroke in the preceding 3 months.
There was no significant change in the number of patients on
angiotensin converting enzyme inhibitors or angiotensin receptor
blockers or their dosages during the study.
All patients had a low baseline 25(OH)D level with a mean level
of 43616 nmol/L; range 13–74 nmol/L (normal reference range
75–200 nmol/L). The calcium levels were within normal limits
2.3760.09 mmol/L (normal reference range 2.2–2.6 mmol/L).
The parathyroid hormone levels were high with a mean of
10.8 pmol/L, range 3–41 pmol/L (normal reference range 1.1–
6.9 pmol/L).
At the end of 16 weeks vitamin D concentrations improved from
43616 to 84629 nmol/L, p,0.001. The calcium increased
(2.3760.09 to 2.4260.09 mmol/L; p = 0.004); and the parathy-
roid hormone decreased (10.868.6 to 7.464.4; p= 0.001). The
estimated GFR (eGFR) and systolic and diastolic blood pressure
remained very stable.
Impact on Vascular function
The brachial artery FMD improved from 3.163.3% to
6.163.7%, p,0.001 (figure 2). The PWV and AI tended to
improve but did not reach statistical significance, as shown in
table 2. There was no significant change in haemoglobin or
haematocrit values during the study.
Impact on blood biomarkers
The circulating biomarkers for endothelial function also showed
an improvement. The E-Selectin decreased from 566662123 to
525662058 pg/mL, p= 0.032. The ICAM-1 levels decreased
from 3.4561.01 to 3.1061.04 ng/mL, p= 0.038. The VCAM-1
level decreased from 54633 to 42633 ng/mL, p= 0.006. The
vWF levels improved, but the change was not statistically
significant 23.7612.2 to 21.6612.2 mU/mL, p= 0.076. There
was no change in hsCRP concentrations or urine protein
creatinine ratio. There was no change in FGF-23 levels before
and after vitamin D therapy (131681 vs. 132667 RU/ml;
p = 0.862).
Discussion
The present study demonstrate that supplementation with
cholecalciferol in stable, moderate CKD was associated with
Table 1. Characteristics of the study population at baseline
(n = 26).
Variables Mean± 1SD or n(%)
Age (years) 50614
Males (%) 19 (73%)
Ethnicity (%)
Caucasian 13 (50%)
South-east Asian 6 (23%)
Afro Caribbean 6 (23%)
Chinese 1 (4%)
Hypertension (%) 22 (87%)
Current Smokers (%) 6 (23%)
Hyperlipidaemia (%) 9 (36%)
Family history of CVD (%) 6 (23%)
History of CVD (%) 3 (11%)
MDRD estimated GFR (ml/min/1.73 m2) 41611
Treatment
ACEi or AT II RA 20 (77%)
Statins 11 (42%)
Aspirin 4 (15%)
Betablockers 4 (15%)
Nitrates 0 (0%)
Legend: Baseline demographics and characteristics of study population that
completed the study: MDRD eGFR: Abbreviated four variable Modified Diet of
Renal Disease estimated Glomerular Filtration Rate48. Mean automated sitting
clinic blood pressure taken thrice using appropriate size cuff was measured.
Hypertension was defined as clinic blood pressure of $140/80 mmHg or on
antihypertensives medications. Diabetes Mellitus was defined by WHO
guidelines 2006 for definition of diabetes. Hyperlipidemia was defined as Total
cholesterol .5 mmol/L and/or LDL.2.5 and or HDL,1.55 or on lipid lowering
therapy (National cholesterol Education Program ATP III guidelines 2001). ACEi-
Angiotensin converting enzyme inhibitor, AT II RA- Angiotensin II receptor
antagonist.
doi:10.1371/journal.pone.0091363.t001
Vitamin D and Endothelial Function in CKD
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e91363
improvement of vascular endothelial function. Vitamin D3
administration over 16 weeks almost doubled the vitamin D
levels, and this was associated with an appropriate decrease in
parathyroid hormone levels. The calcium levels, increased slightly,
but none of the patients developed hypercalcaemia (serum calcium
.2.60 mmol/L). There were reductions in concentrations of
circulating biomarkers of endothelial dysfunction, E-selectin,
ICAM-1 and VCAM-1. There were no changes in hsCRP,
FGF-23 levels and arterial stiffness over the 16 weeks.
In the present study we have measured 25(OH)D, and not 1,25
di-hydroxy vitamin D [1,25(OH)2D], because studies have shown
that the deficiency is reliably related to low 25(OH)D levels and
measurement of 1,25(OH)2D levels is challenging, unreliable and
expensive and therefore not available to most clinicians [25].
Furthermore, 25(OH)D is inexpensive, easy to administer and has
few side effects, even when administered in large doses. Moreover,
studies have shown that 25(OH)D levels do stimulate Vitamin D
receptors, with less affinity but with higher availability for binding
due to its 1000-fold higher concentration in serum [26,27]. There
have been no reports of hypercalcaemia with high dose vitamin D
supplementation in this population, and this was also true in our
study [28].
Vitamin D is an excellent target for treatment in the context of
CKD because of its association with CV disease and endothelial
function. In the general population, vitamin D deficiency is
associated with increased all-cause mortality, as well as CV event
rates [28,29]. In patients with CKD, relationship of low vitamin D
with mortality and CV event rate have been demonstrated in both
dialysis and pre-dialysis patients [15,30]. We and others have
previously demonstrated an association of 25(OH)D deficiency
with endothelial function [14]. However the present study was the
first to investigate the impact of cholecalciferol therapy on
endothelial dysfunction in vitamin D deficient/insufficient pre-
dialysis CKD patients.
Endothelial dysfunction is a harbinger of atherosclerosis. It is
often the first abnormality demonstrated which can predict the
initiation and progression of atherosclerotic artery disease [4]. We
and others have demonstrated highly abnormal endothelial
function in CKD, associated with increased carotid intima-media
thickness, hence it is a possible mechanism of initiation and
progression of atherosclerosis in CKD [5]. In the general
population, endothelial dysfunction within coronary arteries,
predicts future CV events [3]. In large general population studies,
endothelial dysfunction measured by brachial artery FMD predicts
both CV events and mortality [9]. In CKD patients, endothelial
dysfunction is an independent predictor of adverse CV outcomes
[31].
Endothelial function measured in the peripheral arteries has
been used in different patient groups to study the effect of vitamin
D supplementation on vascular function. Amongst several such
studies which we could identify, three studies demonstrated an
improvement of endothelial function with cholecalciferol therapy
but the rest did not. In overweight African-Americans the flow
mediated dilatation improved by 1.8%; in post stroke patients with
FMD improved by 6.9%, and in diabetic patients the FMD
improved by 2.3% [18,32,33]. The studies where vitamin D
therapy was unable to show improvement often used low dose
vitamin D supplementation; such as 1,000 units per day for two
weeks in a randomised control trial of diabetic patients; and 2,500
IU units per day for four months in post menopausal women
[34,35]. It is conceivable that these studies were unable to show a
benefit as the dose of vitamin D used was physiologically
inadequate. In other negative studies, vitamin D was supplement-
ed even when the baseline levels were within normal limits, for
example, in the studies involving post MI and type 2 diabetic
patients, serum 25(OH) D concentrations up to 100 nmol/L at
baseline. Supplementing 25(OH)D3 may not be as effective in
these patients, as supplementing in patients with low 25(OH)D
concentrations [36,37]. Our study included patients with low
25(OH)D and the treatment dose was high.
Impact of Vitamin D on circulating biomarkers of endothelial
function has been variable. In post-MI patients or with coronary
artery disease, E-selectin did not improve with vitamin D, whereas,
in diabetic patients it did [35,37,38]. Our study showed
improvement in E-selectin, VCAM-1, ICAM-1 together with the
improvement in FMD, hence confirming our findings on in-vivo
vascular endothelial function analysis.
CKD patients have immune dysregulation [39,40]. This results
in an increased predisposition to infections as well as chronic
systemic inflammation adversely affecting the CV system. Vitamin
D has pleiotropic effects on the immune system with evidence that
it modulates the adaptive immune system. We know from
experimental studies, that vitamin D down regulates Th1 activity,
dendritic cell maturation and up regulates Th17 regulator activity,
thereby possibly suppressing the low grade inflammation in the
blood vessel and the heart [41–43]. The present study demon-
strated improvement in circulating biomarkers of endothelial
function but did not investigate the mechanism any further.
This study did not demonstrate any change of FGF-23
concentrations with Vitamin D therapy. FGF-23 concentrations
increase with kidney failure and elevated FGF-23 has been
associated with abnormal endothelial function, adverse cardiovas-
cular outcomes, and has recently shown to cause left ventricular
hypertrophy [44]. Vitamin D therapy has usually been shown to
lead to increases in FGF-23 concentrations in CKD and dialysis,
though this effect is not consistent; in our repletion study, we did
not see any effect on FGF-23 concentration [45–47].
This study has demonstrated that abnormal vasomotor and
secretory endothelial function can be rapidly improved with
600,000 IU of Cholecalciferol. There were no adverse changes in
arterial stiffness. However, 16 weeks is too short a time period to
exclude the possibility of later with vitamin D therapy. The rise in
serum calcium concentration was very modest, but was statistically
significant.
Figure 2. Measure of endothelial function before and after
Vitamin D Therapy. Legend: The endothelial function as measured by
brachial artery flow mediated dilatation improves from 3.163.3% to
6.163.7%. Error bars show 95% CI, p,0.001.
doi:10.1371/journal.pone.0091363.g002
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A limitation of this study is that it was conducted over a short
period; so long term effect of vitamin D therapy cannot be
assessed. Logistic reasons precluded randomisation; and potential
bias cannot be excluded. However the study demonstrates
improvement of both endothelial vasomotor and secretory
function with cholecalciferol i.e there were improvements of flow
mediated dilatation as well as the levels of VCAM-1, ICAM-1 and
E-Selectin without adverse effects on arterial stiffness and FGF-23.
These findings strongly suggest an effect of Vitamin D on the
endothelial cells and potentially will lead to further studies
investigating the mechanisms of such benefits of cholecalciferol
on vascular function. The study excluded patients with CKD due
to diabetes; so in this particular patient cohort, which forms a large
proportion of the patients we see in our clinics, these results cannot
be extrapolated. The study was restricted to pre-dialysis stage 3/4
CKD; so in patients with early CKD (stages 1 and 2), post kidney
transplant and dialysis patients the impact of vitamin D
supplementation on endothelial function remains unknown. A
randomised control trial with a longer duration of follow up is
required to confirm the present findings and plan future clinical
outcome driven trials.
In conclusion, this study for the first time demonstrates that
Cholecalciferol improves endothelial vasomotor and secretory
function, in stable non-diabetes stage 3/4 CKD patients without
any significant effect on arterial stiffness, calcium and FGF-23
levels.
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Table 2. Analysis of baseline and follow up parameters after Cholecalciferol therapy.
Variables (n=26) Baseline (week 0) Follow up (16 weeks) p value
Haemoglobin (g/dl) 14.161.8 13.866.7 0.379
Haematocrit (%) 4466 4365 0.486
Serum Albumin (mmol/L) 3666 3864 0.283
Urine Protein Creatinine Ratio (mg/mmol){ 35.76124.2 30.156221.3 0.866
Serum 25 (OH)D (nmol/L) 43616 84629 ,0.001*
Serum Calcium (mmol/L) 2.3760.09 2.4260.09 0.004*
Serum Phosphate (mmol/L) 1.0760.20 1.1060.19 0.459
Serum Parathyroid hormone (pmol/L) 10.868.6 7.464.4 0.001*
MDRD eGFR (ml/min/1.73 m2) 41611 40612 0.559
Systolic Blood Pressure (mmHg) 133612 133617 0.991
Diastolic Blood pressure (mmHg) 8769 85610 0.309
Central pulse pressure (mmHg) 33612 35614 0.349
Baseline brachial artery diameter (mm) 4.660.9 4.660.7 0.945
Endothelium dependent FMD (%) 3.163.3 6.163.7 0.001*
Endothelium independent FMD (%) 7.3464.5 10.3866.7 0.121
PWV (m/s) 7.961.9 7.762.2 0.059
AI (%) 22616 18620 0.055
On ACE I or AT II RA [n(%)] 20(77%) 20(77%) NC
On Statin 11(42%) 11(42%) NC
On Nitrate 0% 0% NC
HsCRP (mg/L){ 3.3564.75 4.0064.42 0.272
E selectin (pg/ml) 566662123 525662058 0.032*
ICAM (ng/ml) 3.4561.01 3.1061.04 0.038*
sVCAM 1 (ng/ml) 54633 42633 0.006*
vWF (mU/ml) 23.7612.2 21.6612.2 0.076
FGF-23 (RU/ml) 131681 132667 0.862
Legend: MDRD eGFR: Abbreviated four variable Modified Diet of Renal Disease estimated Glomerular Filtration Rate (REF). Mean automated, sitting, clinic, blood
pressure taken thrice using appropriate size cuff was recorded.
* denotes p,0.05.
{Distribution non-parametric variable represented as median6IQR, Wilcoxon Signed Rank Test used to analyse the difference in distribution of baseline and follow up
values.
ACE I- Angiotensin converting enzyme inhibitor, AT II RA- Angiotensin II receptor antagonist. NC: No Change.
doi:10.1371/journal.pone.0091363.t002
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